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Background—Ancestral background, specifically African descent, confers higher risk for
development of inhibitory antibodies to factor VIII (FVIII) in hemophilia A. It has been suggested
that differences in the distribution of factor VIII gene (F8) haplotypes, and mismatch between
endogenous F8 haplotypes and those comprising products used for treatment could contribute to
risk.
Design and Methods—Data from the HIGS Combined Cohort were used to determine the
association between F8 haplotype 3 (H3) vs. haplotypes 1 and 2 (H1+H2) and inhibitor risk
among individuals of genetically-determined African descent. Other variables known to affect
inhibitor risk including type of F8 mutation and HLA were included in the analysis. A second
research question regarding risk related to mismatch in endogenous F8 haplotype and recombinant
FVIII products used for treatment was addressed.
Results—H3 was associated with higher inhibitor risk among those genetically-identified
(N=49) as of African ancestry, but the association did not remain significant after adjustment for
F8 mutation type and the HLA variables. Among subjects of all racial ancestries enrolled in HIGS
who reported early use of recombinant products (N=223), mismatch in endogenous haplotype and
the FVIII proteins constituting the products used did not confer greater risk for inhibitor
development.
Conclusion—H3 was not an independent predictor of inhibitor risk. Further, our findings did not
support a higher risk of inhibitors in the presence of a haplotype mismatch between the FVIII
molecule infused and that of the individual.
Keywords
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INTRODUCTION
Data from related and unrelated subjects with hemophilia A clearly indicate that the
immunological outcome of replacement therapy and the risk of developing neutralizing
antibodies (inhibitors) are to a large extent determined by patient-related genetic factors [1,
2]. The most extensively studied genetic risk factor for inhibitors is the causative factor VIII
gene (F8) mutation. Patients with certain types of mutations are at higher risk for the
development of inhibitors than those with others [3]. Other genetic markers of potential
importance for the immune response to the deficient factor include the human leukocyte
antigen (HLA) class II (i.e. DRB1*15 and DQB1*0602) and immune regulatory genes [4–
7]. A two-fold higher incidence of inhibitors in those of African descent compared with
Caucasians further supports the importance of genetic factors [2, 8]. It has been suggested
that this discrepancy may be due to the different distribution of F8 haplotypes by race, with
a higher risk for inhibitors in the case of a mismatch between the proteins encoded by the
endogenous F8 haplotype and those comprising replacement products used for treatment [9,
10]. The haplotypes consist of four nonsynonymous SNPs located across the gene. Each
mutation results in a nonterminating amino acid change in the factor VIII protein
construction. The biologic implications of the amino acid changes have not fully been
explored, but two of the residues are located in immunodominant epitopes, i.e. R484H and
M2238V, whereas R776G and D1241E are located in the B-domain. The haplotypes H3,
H4, and H5 have only been found among blacks, while H1 and H2 are found primarily in
whites and are most commonly present in infused recombinant products [10]. The
Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort was used to further explore
the suggested relationship between haplotype and inhibitor status among those of African
ancestry, and mismatch of haplotype and product use on inhibitor development by
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adjustment for the type of F8 mutation and previously described HLA class II risk alleles
among the subset of HIGS participants.
DESIGN AND METHODS
Study Population
Our data comprised three multi-center studies: the Hemophilia Inhibitor Genetics Study, the
Malmö International Brother Study (MIBS), and the Hemophilia Growth and Development
Study (HGDS) (N=833). The HIGS study group included in the current analysis is
composed of brother pairs, one or both of whom has a history of an inhibitor, and singletons
with a history of inhibitors, enrolled in Europe, North America, Latin America, and South
Africa. The MIBS is composed, almost exclusively, of siblings pairs enrolled in Europe and
North America, and the HGDS is a population-based group enrolled in hemophilia treatment
centers in the US. Data collection from all cohorts included demographics, severity of
hemophilia, history of and current inhibitor status, maximum lifetime Bethesda titer, and
type of F8 mutation. HIGS data collection also included retrospective identification of the
type(s) of replacement products used prior to development of the inhibitor. For those not
having an inhibitor, i.e., brothers of participants with inhibitors, the type(s) of factor used in
the subject’s first 25 exposure days, or in as many exposures to FVIII as his brother had
when his brother developed an inhibitor, were also collected. For the analysis, an inhibitor
was defined as a current or history of an inhibitor ≥1 Bethesda unit (BU).
The procedures followed were in accordance with the ethical standards of the responsible
committees on human experimentation for all three cohorts, and with the Helsinki
Declaration. The MIBS and HIGS are registered at ClinicalTrials.gov.
F8 Haplotyping
To determine factor VIII haplotypes, four non-synonymous single nucleotide
polymorphisms (SNPs) on the F8 gene, G1679A, A2554G, C3951G, and A6940G, were
genotyped using the Assay-on-Demand from Applied Biosystems standard protocols
(www.AppliedBiosystems.com). Haplotypes were constructed using the four markers that
were genotyped. Because the population was almost exclusively male (99.9%), all but one
individual was hemizygous, as all markers are located on the X chromosome. Typing was
completed for all but 7.1% of the markers. An E-M algorithm [11, 12] was used to infer
haplotypes for individuals with missing information. Individuals with missing genotypes
were assigned the haplotype that demonstrated the highest posterior probability. One of the
833 study participants was not haplotyped, reducing the analysis sample to 832.
F8 Mutation Typing and HLA Class II Typing
Approximately 96% percent of the participants in the HIGS Combined Cohort were F8
mutation typed. The remaining 4% of subjects were not typed for either technical reasons or
lack of sufficient DNA. For HIGS and MIBS, if the F8 gene mutation was not already
documented at enrollment, a blood sample was sent for determination to the Institute of
Experimental Haematology and Transfusion Medicine, Bonn, Germany. Standard methods
for the analyses of the F8 gene were used [13]. In HGDS, the presence or absence of an
inversion mutation in the F8 gene was determined for 58% of the HGDS cohort [14]. The
remaining HGDS samples were mutation typed at the Institute of Experimental
Haematology and Transfusion Medicine, Bonn, Germany by the methods outlined above.
Class II HLA genotyping was performed using high-resolution (4-digit) sequence based
typing (SBT) protocols recommended by the 13th International Histocompatibility
Workshop [15]. Typing was completed for 99.9% of the Combined Cohort.
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Recombinant Replacement Products
The recombinant FVIII replacement products included in the current analysis were:
Recombinate, antihemophilic factor concentrate manufactured by Baxter Healthcare
Corporation [16, 17], derived from H2 proteins; Advate, antihemophilic factor produced by
a plasma- and albumin-free method, manufactured by Baxter Healthcare Corporation [18],
also derived from H2 proteins; and Kogenate, antihemophilic factor manufactured by Bayer
HealthCare Pharmaceuticals [19], derived from H1 proteins.
Statistical Analysis
Association tests, including Fisher’s exact test, were carried out using two by two tables to
evaluate the probability of inhibitor occurrence. GEE models were used to account for the
relatedness of participants. However, for the recombinant treatment analysis, in which there
were 43 family groups consisting of brother pairs or trios among the 223 recombinant
product users, GEE models could not be used due to sample size limitations. For this
analysis only, the model was reduced to a logistic regression. The outcome variable in the
analysis was the presence or absence of a history of inhibitors to FVIII, and the effect of
interest was the endogenous F8 haplotype. The use of genetic information allows for a more
powerful method of classifying the ancestry of an individual than data obtained by self-
reported cultural identity or race. Principal components were constructed with EIGENSOFT
[20], using an additional 13,331 SNPs spaced across the genome to describe population
structure. F8 gene mutations were categorized as high risk: inversions, large deletions,
nonsense, small deletions/insertions (outside A-runs), missense (Arg593Cys, Tyr2105Cys,
Arg2150His, Arg2163His, Trp2229Cys, Pro2300Leu, and Asn2286Lys), and splice site (at
conserved nucleotides at position + or − 1 and 2); or low risk: small deletions/insertions
(within A-runs), splice site (at position + or − 3 or more remote), missense (other regions),
or other mutation types. A third category contained those for whom no mutation was found.
A multiple imputation (MI) procedure [21] was carried out using SAS PROC MI [22] to
identify risk category for two genetically-black individuals missing this variable. The MI
procedure allows imputation of categorical and ordinal variables through the use of logistic
regression models. The variables used to predict mutation risk were haplotype, HLA allele
count, severity of hemophilia, principal components, year of birth and family relatedness.
Imputations were performed by inhibitor status to allow for possible distributional
differences in mutation risk for those with and without inhibitors. For the HLA class II
alleles of interest, DRB1*15 and DQB1*0602, analysis was performed based on the number
of copies of the allele (i.e., 0, 1 or 2 alleles). Models were analyzed using SAS 9.2.
RESULTS
Descriptors of the population are shown in Table 1. The H1, H2 and H3 haplotypes were
observed in all four racial categories (Table 2), with the highest prevalence of H3 occurring
in the genetically-determined black population (28.6%). The H4 and H5 haplotypes were not
observed in any participants. The haplotype distribution by race in the HIGS Combined
Cohort was generally similar to that reported by Viel [10]. A consideration when using the
EM algorithm to impute missing genotypes is to establish that the missingness is at random,
and not confounded with other predictors such as F8 mutation. To ensure that the imputation
of missing genotypes using the EM algorithm was appropriate, the missing genotypes were
compared to F8 mutation type. None of the marker positions showed an association with
mutation type, indicating that the missingness was not likely due to a particular type of
mutation. Additionally, none of the haplotypes showed associations with the mutation types
(Table 3).
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Haplotype, Race, and Inhibitors
We evaluated the effect of the H3 haplotype on inhibitor status. The white, Hispanic and
other populations contained fewer than 3 copies of H3 each, therefore the effect was
examined only for the 49 genetically-determined black individuals, 14 of whom had the H3
haplotype. Testing the prevalence of H3 haplotype compared to the H1 and H2 haplotypes
on inhibitor status in the group, adjusted for family, the OR was 2.10, p=0.009. Mutation
risk category and HLA allele counts were introduced to the model. The effect of haplotype
on inhibitor development with mutation risk included in the model was a reduction in risk
for H3 haplotype (OR 1.37, p=0.31), and a significant effect of high risk mutations (OR
4.95, p=0.0046). Adjustment for HLA allele count covariates resulted in an OR for H3 of
1.69, p=0.33. When all variables were considered together (H3 haplotype, mutation risk
category, and HLA), only mutation was a significant predictor of inhibitor status (OR 8.17,
p=0.0032). Although our sample size was small (n=49 in all models), it provided sufficient
coverage for the parameters entered into the model.
Haplotype, Recombinant Product Use, and Inhibitors
The most commonly used recombinant products for the treatment of FVIII deficiency are
derived from H1 (Kogenate) and H2 (Recombinate, Advate) proteins. Early treatment with a
recombinant product was reported for 224 participants in HIGS, 91 (40.6%) using H1
products and 87 (38.8%) using H2 products. The remaining participants used a b-domain
deleted product or were on multiple or unknown recombinant products (20.6%), and were
therefore ineligible for the analyses.
Of the participants with early recombinant product use, 223 also had haplotype information.
In this subset, 72 (79.1%) of the 91 individuals using the H1 product had an inhibitor. The
association between haplotype (H2 + H3 vs. H1) and inhibitor status among the participants
who received H1 products was tested. The results (Table 5) showed no significant
association between haplotype and inhibitor status (OR 0.76 of H2 or H3 having an
inhibitor, p=0.71). Among the group of 86 participants receiving the H2 products, 69 (80%)
individuals had an inhibitor. No significant effect was found (OR 1.18 of those with H1 or
H3 having an inhibitor, p=1.0) when comparing the occurrence of inhibitors in the H1+H3
vs. H2 haplotype groups among those who used an H2 product.
DISCUSSION
The frequency of haplotypes observed was consistent with those previously reported by Viel
[10], indicating that our population is similar in genetic F8 composition to that previously
analyzed. We had fewer individuals of African ancestry and the magnitudes of our estimates
of risk for inhibitors among those with the H3 haplotype were somewhat lower, but our data
support the findings by Viel et al. prior to adjustment for other factors. After adjustment for
covariates including the F8 gene mutation and HLA class II alleles DRB1*15 and
DQB1*0602, the association between H3 haplotype and inhibitor risk is no longer
significant. Having a high risk F8 gene mutation remains a significant risk factor. This
indicates that the effect previously described by Viel, et al. is, in our cohort, largely
explained by other genetic factors, primarily the F8 mutation. The genetically-determined
racial classification used in our investigation may be more accurate than self-report because
it is based on differences in allele frequencies that occur among distinct human populations
rather than on cultural identity. Use of genetic data to classify ancestry complements the
hypothesis that additional, so far unknown, genetic markers will likely explain the higher
inhibitor risk in blacks, as has been the case for other immune-mediated disorders that are
more prevalent in this population.
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As noted above, our study used principal components to genetically determine ancestry.
This method requires a set of genome-wide markers to capture the allele frequency
differences between ancestral backgrounds. In instances where a whole genome wide panel
of genetic markers is not available, other methods can be used. Use of pattern mixture
models based on a specific category of markers was developed by Pritchard, et al. [23]. The
pattern mixture models require markers that are known to exhibit polymorphism between
racial groups. The set generally consists of, at most, several hundred markers and are
selected based on the different racial groups believed to be in the population of interest.
The analysis performed on the type of recombinant FVIII products used for early treatment
addresses a different research question. It supports the hypothesis of no association between
haplotype and current or history of an inhibitor. Neither of the two recombinant products
examined were associated with a greater proportion of inhibitors for mismatched haplotypes.
The size of our study group was sufficient to detect any large effect, but with an observed
OR of only 0.76 (risk of H2 or H3 developing an inhibitor after exposure to an H1 product)
and 80% power, it would take 2,518 participants to see a significant result. With an OR of
only 1.18 (risk of H1 or H3 developing an inhibitor after exposure to an H2 product) and
80% power, 7,030 participants would be required to see a significant result.
In conclusion, our findings do not support a substantially higher risk of inhibitors in the
presence of a haplotype mismatch between the FVIII molecule infused and that of the
individual.
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APPENDIX
Participating HIGS investigators and centers in order of contribution: Liesner, Raina, Great
Ormond Street Hospital for Children NHS Trust, London, UK; Windyga, Jerzy, and
Klukowska, Anna, Institute of Hematology and Blood Transfusion, Warsaw, Poland;
Kavakli, Kaan, Ege University Hospital, Izmir, Turkey; Santagostino, Elena, and Mancuso,
Maria Elisa, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy;
DiMichele, Donna, and Giardina, Patricia, Weill Cornell Medical College, New York, USA;
Rivard, Georges, Hôpital Ste-Justine, Montreal, Canada; Oldenburg, Johannes, University
Clinic Bonn, Bonn, Germany; van den Berg, Marijke, and Schutgens, R., University
Medical Center Utrecht, Utrecht, Netherlands; Ewing, Nadia, City of Hope National
Medical Center, Duarte, USA; Astermark, Jan, Centre for Thrombosis and Haemostasis,
Lund University, Skåne University Hospital Malmö, Malmö, Sweden; Mäkipernaa, Anne,
Clinical Research Institute Helsinki, Helsinki, Finland; Schwyzer, Rosemary, Johannesburg
Hospital, Johannesburg, South Africa; Shapiro, Amy, Indiana Hemophilia and Thrombosis
Center, Indianapolis, USA; Altisent, Carmen, Hospital Vall d’Hebron, Barcelona, Spain;
Peréz Bianco, Raúl, Academia Nacional de Medicina, Buenos Aires, Argentina; Ducore,
Jonathan, University of California, Davis, Sacramento, USA; Leissinger, Cindy, Louisiana
Comprehensive Hemophilia Care Center, Tulane University, New Orleans, USA; Ruiz-Sáez,
Arlette, Centro Nacional de Hemofilia, Caracas, Venezuela; Collins, Peter, Arthur Bloom
Haemophilia Center, Cardiff, Wales; Monahan, Paul, UNC Comprehensive Hemophilia
Center, Chapel Hill, USA; Peters, Marjolein, Academisch Medisch Centrum, Amsterdam,
The Netherlands; Valentino, Leonard, Rush University Medical Center, Chicago, USA;
Alvárez, Mayte, and Jíminez-Yuste, Victor, La Paz University Hospital, Madrid, Spain;
Chalmers, Elizabeth, Royal Hospital for Sick Children, Glasgow, Scotland; Jurgutis,
Romualdas, Klaipėdos Jūrininkų Ligonine, Klaipėda, Lithuania; Kouides, Peter, Rochester
General Hospital, Rochester, USA; Pollman, Hartmut, Hemophilia Center and Institute for
Thrombosis and Hemostasis, Mūnster, Germany; Thornburg, Courtney, Duke University,
Durham, USA; Huang, James, University of California, San Francisco, USA; Male,
Christoph, Medizinische Universität Wien, Vienna, Austria; Önundarson, Páll, Landspitali
University Hospital, Reykjavik, Iceland; Solano, María Helena, Hospital San Jose, Bogota,
Colombia; Cnossen, M.H., Erasmus Medical Center, Rotterdam, The Netherlands; Escobar,
Miguel, University of Texas Health Science Center at Houston, Houston, USA; Gomperts,
Edward, Childrens Hospital Los Angeles, Los Angeles, USA; Iyer, Rathi, University of
Mississippi Medical Center, Jackson, USA; Makris, Michael, Sheffield Haemophilia and
Thrombosis Center, Royal Hallamshire Hospital, Sheffield, UK; Rangarajan, Savita, Guy’s
and St. Thomas’s NHS Foundation Trust, London, UK; Warrier, Indira, and Chitlur, Meera,
Children’s Hospital of Michigan, Detroit, USA; de Moerloose, Philippe, Hôpital
Universitaire de Genève, Geneva, Switzerland; Evans, Gillian, Kent and Canterbury
Hospital, Canterbury, UK; Gruppo, Ralph, Cincinnati Children’s Hospital Medical Center,
Cincinnati, USA; Janic, Dragana, University Children’s Hospital, Belgrade, Serbia; Micic,
Dragan, Mother and Child Health Care Institute of Serbia “Dr. Vukan Cupic”, Belgrade,
Serbia.
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Table 1
Summary of variables by cohort
HGDS (n=265) HIGS (n=448) MIBS (n=120)
With Inhibitor ≥1 BU (n, %) 52 (20%) 360 (80%) 45 (38%)
Race (n, %) (n=265) (n=448) (n=119)
Asian 0 (0%) 10 (2%) 0 (0%)
Black 24 (9%) 23 (5%) 2 (2%)
Hispanic 42 (16%) 50 (11%) 0 (0%)
White 195 (74%) 346 (77%) 115 (97%)
Other 4 (2%) 19 (4%) 2 (2%)
Hemophilia Severity HGDS (n=265) HIGS (n=448) MIBS (n=120)
Mild 16 (6%) 0 (0%) 14 (12%)
Moderate 50 (19%) 0 (0%) 19 (16%)
Severe 199 (75%) 448 (100%) 87 (73%)
Haplotype (n, %) (n=265) (n=447) (n=120)
H1 202 (76%) 377 (84%) 98 (82%)
H2 56 (21%) 61 (14%) 21 (18%)
H3 7 (3%) 9 (2%) 1 (1%)
Treatment with a full-length recombinant product (n, %)
Kogenate - 91 (51%) -
Recombinate/Advate - 87 (49%) -
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Table 3
F8mutation type* by haplotype
Mutation Type H1 (n=654) H2 (n=131) H3 (n=16)
Inversion 330 (50.5%) 65 (49.6%) 8 (50.0%)
Large Deletion 36 (5.5%) 3 (2.3%) 0 (0%)
Missense Mutation 82 (12.5%) 16 (12.2%) 4 (25.0%)
Nonsense Mutation 47 (7.2%) 13 (10.0%) 1 (6.3%)
Small Deletion/Insertion 68 (10.4%) 16 (12.2%) 3 (18.8%)
Splice Site Mutation 11 (1.7%) 2 (1.5%) 0 (0%)
No Inversion, or otherwise not determined 76 (11.6%) 15 (11.4%) 0 (0%)
Other 4 (0.6%) 1 (0.8%) 0 (0%)
*F8 mutation type was missing for N=31 (3.7%)
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Table 4
The effect of F8 haplotype 3 on inhibitor development in genetically-identified black participants.
Model Covariate
Genetically-identified Black Participants (N=49)
OR 95% CI P-value
1. Haplotype Only
Haplotype (H3 vs. H1+H2) 2.10 (1.20, 3.68) 0.0092
2. Haplotype + Mutation
Haplotype (H3 vs. H1+H2) 1.37 (0.74, 2.55) 0.3143
Mutation Risk (High vs. Low) 4.95 (1.64, 14.93) 0.0046
3. Haplotype + HLA
Haplotype (H3 vs. H1+H2) 1.69 (0.59, 4.86) 0.3265
DQB 0602 1.39 (0.31, 6.25) 0.6692
DR 15 1.22 (0.41, 3.63) 0.7246
4. Haplotype + HLA + Mutation
Haplotype (H3 vs. H1+H2) 0.90 (0.34, 2.41) 0.8387
DQB 0602 4.44 (0.71, 27.61) 0.1097
DR 15 0.73 (0.21, 2.52) 0.6223
Mutation Risk (High vs. Low) 8.17 (2.02, 32.96) 0.0032
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